{
    "clinical_study": {
        "@rank": "75559", 
        "arm_group": [
            {
                "arm_group_label": "Albuterol Spiromax 90 mcg", 
                "arm_group_type": "Experimental", 
                "description": "At each treatment visit, participants receive 1 actuation from each of 4 pre-arranged device combinations comprising 2 dry powder inhalers (DPIs) and 2 metered-dose inhalers (MDIs) in order to maintain the study blind.  The DPIs could contain Albuterol Spiromax 90 mcg or placebo.  The MDIs could contain ProAir HFA 90 mcg or placebo.\nIn this arm, one of the DPIs contains Albuterol Spiromax 90 mcg."
            }, 
            {
                "arm_group_label": "Albuterol Spiromax 180 mcg", 
                "arm_group_type": "Experimental", 
                "description": "At each treatment visit, participants receive 1 actuation from each of 4 pre-arranged device combinations comprising 2 dry powder inhalers (DPIs) and 2 metered-dose inhalers (MDIs) in order to maintain the study blind.  The DPIs could contain Albuterol Spiromax 90 mcg or placebo.  The MDIs could contain ProAir HFA 90 mcg or placebo.\nIn this arm, both of the DPIs contain Albuterol Spiromax 90 mcg for a total dose of 180 mcg."
            }, 
            {
                "arm_group_label": "ProAir HFA 90 mcg", 
                "arm_group_type": "Active Comparator", 
                "description": "At each treatment visit, participants receive 1 actuation from each of 4 pre-arranged device combinations comprising 2 dry powder inhalers (DPIs) and 2 metered-dose inhalers (MDIs) in order to maintain the study blind.  The DPIs could contain Albuterol Spiromax 90 mcg or placebo.  The MDIs could contain ProAir HFA 90 mcg or placebo.\nIn this arm, one of the MDIs contains ProAir HFA 90 mcg."
            }, 
            {
                "arm_group_label": "ProAir HFA 180 mcg", 
                "arm_group_type": "Active Comparator", 
                "description": "At each treatment visit, participants receive 1 actuation from each of 4 pre-arranged device combinations comprising 2 dry powder inhalers (DPIs) and 2 metered-dose inhalers (MDIs) in order to maintain the study blind.  The DPIs could contain Albuterol Spiromax 90 mcg or placebo.  The MDIs could contain ProAir HFA 90 mcg or placebo.\nIn this arm, both of the MDIs contain ProAir HFA 90 mcg for a total dose of 180 mcg."
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "At each treatment visit, participants receive 1 actuation from each of 4 pre-arranged device combinations comprising 2 dry powder inhalers (DPIs) and 2 metered-dose inhalers (MDIs) in order to maintain the study blind.  The DPIs could contain Albuterol Spiromax 90 mcg or placebo.  The MDIs could contain ProAir HFA 90 mcg or placebo.\nIn this arm, all device combinations contain placebo."
            }
        ], 
        "brief_summary": {
            "textblock": "This is a multicenter, randomized, double-blind, double-dummy, placebo-controlled,\n      single-dose, 5-treatment, 5-period, 5-way crossover study in pediatric patients with\n      persistent asthma. The primary purpose of this study is to compare the efficacy and safety\n      of Albuterol Spiromax with that of ProAir HFA in pediatric asthma patients at 2 delivered\n      dose levels equivalent to 90 mcg and 180 mcg of albuterol base."
        }, 
        "brief_title": "Efficacy and Safety Comparison of Albuterol Spiromax\u00ae and ProAir\u00ae Hydrofluoroalkane (HFA) in Pediatric Patients", 
        "completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "condition": "Asthma", 
        "condition_browse": {
            "mesh_term": "Asthma"
        }, 
        "detailed_description": {
            "textblock": "The study consists of a screening visit (SV) followed by up to 16 days by a treatment period\n      comprising 5 visits (TV1-TV5). The treatment period visits will each be separated by a\n      washout period lasting 2-7 days. During each treatment period visit, the forced expiratory\n      volume in 1 second (FEV1) will be determined at 30 minutes and again immediately prior to\n      the commencement of study medication administration, and 5, 15, 30, 45, 60, 120, 180, 240,\n      300, and 360 minutes after completion of study medication administration."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Written informed consent/assent signed and dated by the patient and/or\n             parent/caregiver/legal guardian (as appropriate) before conducting any study related\n             procedure\n\n          2. Male or pre-menarchal female 4-11 years of age, inclusive, as of the screening visit\n\n          3. Has a documented physician diagnosis of persistent asthma of a minimum of 6 months\n             duration that has been stable for at least 4 weeks prior to the screening visit. The\n             asthma diagnosis must be in accordance with the National Asthma Education and\n             Prevention Program Guidelines Expert Panel Report 3 (EPR3)\n\n          4. Has the ability to self-perform spirometry reproducibly per American Thoracic Society\n             (ATS) guidelines\n\n          5. Has forced expiratory volume in 1 second (FEV1) 60-90% predicted for age, height, and\n             gender at the screening visit based on the pediatric population standards as per\n             protocol.\n\n             Notes: (1) Predicted values of 59.50-59.99% may be rounded up to 60% and 90.01-90.49%\n             rounded down to 90%. (2) Patients who at the screening visit fail to meet the\n             predicted spirometry values for study entry may be allowed a single attempt to\n             re-qualify on another day, but they must re-qualify no later than 16 days following\n             the first attempt.\n\n          6. Demonstrates reversible bronchoconstriction as verified by a 15% or greater increase\n             in baseline FEV1 within 30 minutes following inhalation of 180 mcg of albuterol to\n             200 mcg of fluticasone propionate per day or equivalent), leukotriene modifiers\n             (LTM), inhaled cromones, or on \u03b22-agonists alone as needed.  The Inhaled\n             corticosteroid (ICS), LTM, and cromone doses must have been stable for at least 4\n             weeks prior to the screening visit and are expected to be maintained for the duration\n             of the study\n\n          7. Is maintained on low-dose inhaled corticosteroids ([ICS], less than or equal to 200\n             mcg of fluticasone propionate per day or equivalent), leukotriene modifiers (LTM),\n             inhaled cromones, or on \u03b22-agonists alone as needed. The ICS, LTM, and cromone doses\n             must have been stable for at least 4 weeks prior to the screening visit and are\n             expected to be maintained for the duration of the study\n\n          8. Can self-perform peak expiratory flow rate (PEF) measurements with a handheld peak\n             flow meter\n\n          9. Has the ability to demonstrate acceptable and reproducible inhalation technique with\n             the Spiromax and metered dose inhaler (MDI) devices\n\n               -  Other inclusion criteria apply.\n\n        Exclusion Criteria:\n\n          1. Known hypersensitivity to albuterol or any of the excipients in the inhaler\n             formulations (lactose, ethanol, etc.)\n\n          2. Participation (receiving study medication) in any investigational drug trial within\n             the 30 days preceding the screening visit or planned participation in another\n             investigational drug trial at any time during this trial\n\n          3. History of severe milk protein allergy\n\n          4. History of a respiratory infection or disorder (including, but not limited to\n             bronchitis, pneumonia, acute or chronic sinusitis, otitis media, influenza, etc.)\n             that has not resolved within 4 weeks preceding the screening visit\n\n          5. Any asthma exacerbation requiring oral corticosteroids within 3 months of the\n             screening visit. A patient must not have had any hospitalization for asthma within 6\n             months prior to the screening visit.\n\n          6. History of life-threatening asthma that is defined for this protocol as an asthma\n             episode that required intubation and/or was associated with hypercapnea, respiratory\n             arrest, or hypoxic seizures\n\n          7. Use of any prohibited concomitant medications within the washout period prescribed\n             per protocol prior to the screening visit.\n\n          8. Use of any medication for asthma or allergic rhinitis that is prohibited per the\n             protocol\n\n          9. The dosage of any required intranasal corticosteroid and/or cromone has not been\n             stable for at least 2 weeks prior to the screening visit.\n\n         10. Treated with oral or injectable corticosteroids within the 6 weeks before the\n             screening visit.\n\n         11. Initiation of immunotherapy during the study period or dose escalation during the\n             study period. Patients being treated with immunotherapy prior to the screening visit\n             must be using a stable (maintenance) dose (90 days or more) to be considered for\n             inclusion."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "11 Years", 
            "minimum_age": "4 Years"
        }, 
        "enrollment": {
            "#text": "61", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "July 8, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01899144", 
            "org_study_id": "ABS-AS-202"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Albuterol Spiromax 90 mcg", 
                    "Albuterol Spiromax 180 mcg"
                ], 
                "description": "Albuterol Spiromax\u00ae Inhalation Aerosol contains 90 mcg albuterol per actuation orally inhaled in a single dose dry powder inhaler (DPI).  Participants took doses at either the 90 or 180 mcg levels.  If the higher level, two DPIs filled with Albuterol Spiromax\u00ae were used.", 
                "intervention_name": "Albuterol Spiromax", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Spiromax\u00ae", 
                    "albuterol"
                ]
            }, 
            {
                "arm_group_label": [
                    "ProAir HFA 90 mcg", 
                    "ProAir HFA 180 mcg"
                ], 
                "description": "ProAir\u00ae HFA Inhalation Aerosol contains 90 mcg albuterol per actuation orally inhaled in a single dose metered dose inhaler (MDI).  Participants took doses at either the 90 or 180 mcg levels.  If the higher level, two MDIs filled with ProAir HFA were used.", 
                "intervention_name": "ProAir HFA", 
                "intervention_type": "Drug", 
                "other_name": "ProAir\u00ae"
            }, 
            {
                "arm_group_label": [
                    "Albuterol Spiromax 90 mcg", 
                    "Albuterol Spiromax 180 mcg", 
                    "ProAir HFA 90 mcg", 
                    "ProAir HFA 180 mcg", 
                    "Placebo"
                ], 
                "description": "Single dose MDIs and DPIs containing placebo taken as a single orally-inhaled actuation each.", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Albuterol", 
                "Procaterol"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Albuterol Spiromax", 
            "ProAir HFA", 
            "albuterol sulfate"
        ], 
        "lastchanged_date": "November 13, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Birmingham", 
                        "country": "United States", 
                        "state": "Alabama"
                    }, 
                    "name": "Teva Investigational Site 10598"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Little Rock", 
                        "country": "United States", 
                        "state": "Alaska"
                    }, 
                    "name": "Teva Investigational Site 10593"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Costa Mesa", 
                        "country": "United States", 
                        "state": "California"
                    }, 
                    "name": "Teva Investigational Site 10610"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Huntington Beach", 
                        "country": "United States", 
                        "state": "California"
                    }, 
                    "name": "Teva Investigational Site 10582"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Orange", 
                        "country": "United States", 
                        "state": "California"
                    }, 
                    "name": "Teva Investigational Site 10606"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Jose", 
                        "country": "United States", 
                        "state": "California"
                    }, 
                    "name": "Teva Investigational Site 10597"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Jacksonville", 
                        "country": "United States", 
                        "state": "Florida"
                    }, 
                    "name": "Teva Investigational Site 10596"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lawrenceville", 
                        "country": "United States", 
                        "state": "Georgia"
                    }, 
                    "name": "Teva Investigational Site 10599"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Savannah", 
                        "country": "United States", 
                        "state": "Georgia"
                    }, 
                    "name": "Teva Investigational Site 10580"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Normal", 
                        "country": "United States", 
                        "state": "Illinois"
                    }, 
                    "name": "Teva Investigational Site 10592"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Missoula", 
                        "country": "United States", 
                        "state": "Montana"
                    }, 
                    "name": "Teva Investigational Site 10602"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Raleigh", 
                        "country": "United States", 
                        "state": "North Carolina"
                    }, 
                    "name": "Teva Investigational Site 10578"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Oklahoma City", 
                        "country": "United States", 
                        "state": "Oklahoma"
                    }, 
                    "name": "Teva Investigational Site 10577"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Medford", 
                        "country": "United States", 
                        "state": "Oregon"
                    }, 
                    "name": "Teva Investigational Site 10589"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Portland", 
                        "country": "United States", 
                        "state": "Oregon"
                    }, 
                    "name": "Teva Investigational Site 10604"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Charleston", 
                        "country": "United States", 
                        "state": "South Carolina"
                    }, 
                    "name": "Teva Investigational Site 10591"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Orangeburg", 
                        "country": "United States", 
                        "state": "South Carolina"
                    }, 
                    "name": "Teva Investigational Site 10609"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Spartanburg", 
                        "country": "United States", 
                        "state": "South Carolina"
                    }, 
                    "name": "Teva Investigational Site 10579"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boerne", 
                        "country": "United States", 
                        "state": "Texas"
                    }, 
                    "name": "Teva Investigational Site 10588"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New Braunfels", 
                        "country": "United States", 
                        "state": "Texas"
                    }, 
                    "name": "Teva Investigational Site 10605"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Antonio", 
                        "country": "United States", 
                        "state": "Texas"
                    }, 
                    "name": "Teva Investigational Site 10583"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Waco", 
                        "country": "United States", 
                        "state": "Texas"
                    }, 
                    "name": "Teva Investigational Site 10576"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "5", 
        "official_title": "A Single-Dose, Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Five-Period Crossover, Dose-Ranging Efficacy and Safety Comparison of Albuterol Spiromax\u00ae and ProAir\u00ae HFA in Pediatric Patients With Persistent Asthma", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "October 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "The percent predicted FEV1 (PPFEV1) area under the curve (AUC)0-6 will be calculated using the linear trapezoidal rule, and baseline adjustment will be made by subtracting the average of the 2 pre-dose PPFEV1 values from each post-dose PPFEV1 determination. If only 1 pre-dose FEV1 determination is available, that value will be taken as the baseline.", 
            "measure": "Area-under-the-percent-predicted FEV1 vs time curve over 6 hours post dose", 
            "safety_issue": "No", 
            "time_frame": "Pre-dose to 6 hours post-dose"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01899144"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Area under the FEV1 versus time curve over 6 hours post dose", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose to 6 hours post-dose"
            }, 
            {
                "measure": "Summary of Participants with Adverse Events as a measure of safety", 
                "safety_issue": "Yes", 
                "time_frame": "Day 1 up to day 28"
            }
        ], 
        "source": "Teva Pharmaceutical Industries", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Teva Pharmaceutical Industries", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}